Cast21 is a Chicago‑based medical‑device company that builds a patented, waterproof, breathable immobilization system — an alternative to traditional plaster or fiberglass casts — aimed at speeding application, improving patient comfort, and enabling clinicians to visualize and manage wounds while patients stay active during recovery[5][2].
High‑Level Overview
- Mission, investment‑firm fields not applicable — Cast21 is a portfolio company / medical device firm whose mission is to create solutions that improve lives and to change the way the world heals[6].
- Product and customers: Cast21 manufactures the Cast21 immobilization net (a sleeve and a liquid resin “pack”) that hardens in minutes to form a lightweight, molded orthosis used in orthopedics, sports medicine, pediatrics, family medicine and urgent care[2][5].
- Problem solved: It replaces messy, slow‑to‑apply plaster/fiberglass casts with a waterproof, breathable, quick‑setting device that allows showering, wound visualization, and greater patient comfort[5][4].
- Growth momentum: Founded in 2015–2016, Cast21 has moved through university incubation and accelerator programs, achieved FDA listing/clearance as described on the company site and blog, raised several rounds including ~$4.7M total and debt financing, and has partnership and distribution activity consistent with early commercial expansion[4][1][2].
Origin Story
- Founding and team: Cast21 was founded around 2015–2016 in Chicago; cofounder and CEO Ashley Moy has a bioengineering background from the University of Illinois and the company emerged from university entrepreneurship programs and Research Park/EnterpriseWorks support[4][1].
- How the idea emerged: The product was developed to address the well‑known drawbacks of traditional casts (weight, moisture obstruction, inability to inspect wounds), leveraging a patent‑pending fillable sleeve + fast‑curing resin system to produce a custom‑molded immobilizer in minutes[5][2].
- Early traction / pivotal moments: Early milestones include graduating from university incubators, receiving NSF/agency support and grants, filing multiple patents, achieving FDA listing and initial commercialization efforts and partnerships with health organizations[4][1][2].
Core Differentiators
- Rapid application: System applies in roughly three minutes in three steps (position sleeve, fill with fast‑curing resin, allow to harden), avoiding the longer set times of traditional casts[5].
- Waterproof & breathable design: Open lattice and materials allow showering and air flow while maintaining immobilization, improving hygiene and patient quality of life versus plaster/fiberglass[5][4].
- Wound visibility and clinical access: Open design enables clinicians to inspect and dress wounds without removing the device, aiding wound care and monitoring[4][5].
- Patented system + regulatory progress: Company cites multiple patents and FDA‑listed device status, supporting defensibility and clinical adoption[1][2].
- Lightweight, customizable fit: The liquid‑filled sleeve hardens to a molded shape, providing a tailored fit with potentially lower weight than traditional casts[5][2].
Role in the Broader Tech & Healthcare Landscape
- Trend alignment: Cast21 rides the trend toward patient‑centric, outpatient‑friendly medical devices that reduce care friction and enable faster clinic throughput[5][4].
- Why timing matters: Increasing emphasis on value‑based care, shorter clinic visits, improved patient experience, and infection‑control/wound‑management needs favors innovations that replace bulky, non‑breathable immobilizers[4][5].
- Market opportunity: The global market for casts and splint supplies has been estimated in prior analyses at over a billion dollars, creating room for differentiated entrants that offer clinical and patient advantages[4].
- Ecosystem influence: By commercializing a clinician‑friendly, quick‑apply device and engaging hospitals/urgent care, Cast21 can shift standard of care for common fractures and sprains and spur competitors to improve materials and workflows[5][1].
Quick Take & Future Outlook
- What’s next: Near‑term priorities likely include scaling commercial distribution across hospitals, urgent care and sports medicine channels, expanding payer/reimbursement clarity, and broadening clinical evidence to accelerate adoption[1][5].
- Trends that will shape them: Demonstrated outcomes (healing, re‑visit rates), cost/benefit vs. standard casting, hospital procurement cycles, and regulatory/reimbursement developments will determine velocity of uptake[4][1].
- Possible evolution: If Cast21 continues to build clinical evidence, secure broader reimbursement, and expand manufacturing, it can become a mainstream alternative to traditional casts and influence design standards for external immobilization[2][5].
Quick reminder: Cast21 is a company (not an investment firm); the above synthesizes public company material, accelerator/university profiles, and industry‑facing content from the company’s website and business databases[5][4][1][2].
